| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Inovio Pharmaceuticals (NASDAQ:INO) reported its Q4 earnings results on Wednesday, March 6, 2024 at 06:30 AM.
Here's what investors need to know about the announcement.
Inovio Pharmaceuticals beat estimated earnings by 13.0%, reporting an EPS of $-1.1 versus an estimate of $-1.27.
Revenue was down $22 thousand from the same period last year.
Last quarter the company missed on EPS by $0.0 which was followed by a 4.0% drop in the share price the next day.
Here's a look at Inovio Pharmaceuticals's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.56 | -1.68 | -1.68 | -2.04 |
| EPS Actual | -1.56 | -1.56 | -1.92 | -2.64 |
| Revenue Estimate | 120K | 260K | 270K | 340K |
| Revenue Actual | 388K | 225K | 114K | 125K |
To track all earnings releases for Inovio Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INO
